Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction
Double-Blind, Multicenter Phase 3 Study Comparing the Efficacy and Safety of OMS103HP With Vehicle in Patients Undergoing Autograft ACL Reconstruction
1 other identifier
interventional
326
2 countries
18
Brief Summary
The anterior cruciate ligament (ACL) is an important stabilizer of the knee. Orthopedic surgeons replace the torn ligament during ACL reconstruction surgery. Surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of function. OMS103HP was designed to deliver targeted therapeutic agents directly to the surgical site during the arthroscopic procedure to inhibit inflammation and pain before they can begin. The purpose of this study is to assess the effectiveness and safety of OMS103HP in improving knee function following ACL reconstruction using a hamstring autograft. Secondary benefits being evaluated include reduced postoperative pain, improvement in knee range of motion, and earlier return to work.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jun 2005
Longer than P75 for phase_3
18 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 26, 2005
CompletedFirst Posted
Study publicly available on registry
September 27, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2011
CompletedOctober 12, 2012
October 1, 2012
5.3 years
September 26, 2005
October 10, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Improvement in knee function
30 days
Secondary Outcomes (3)
Decreased pain
30 days
Improved range of motion
30 days
Earlier return to work
30 days
Study Arms (2)
OMS103HP irrigation solution
EXPERIMENTALDrug
vehicle irrigation solution
PLACEBO COMPARATORVehicle
Interventions
Eligibility Criteria
You may qualify if:
- years of age
- In good general health with an ACL tear that occurred from 2 weeks to 18 months prior to the day of arthroscopic surgery
- Undergoing primary unilateral ACL reconstruction using a medial hamstring (semitendinosus and gracilis) autograft
- Able to participate in the study rehabilitation protocol
You may not qualify if:
- Allergies to any of the individual ingredients in OMS103HP
- Taking medications with the same activities as that of the active ingredients in OMS103HP for defined time intervals prior to and after surgery
- Associated knee injuries likely to interfere with evaluation of the study drug
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (18)
CORE Orthopaedic Medical Center
Encinitas, California, 92024, United States
Advanced Orthopedic and Sports Medicine Specialists
Denver, Colorado, 80230, United States
Colorado Orthopedic Consultants, PC
Englewood, Colorado, 80110, United States
University of Florida
Gainesville, Florida, 32611, United States
William Beaumont Hospital
Royal Oak, Michigan, 48073, United States
Minnesota Sports Medicine
Minneapolis, Minnesota, 55454, United States
University Orthopedics Center - Altoona
Altoona, Pennsylvania, 16602, United States
University Orthopedics Center
State College, Pennsylvania, 16801, United States
Texas Orthopedics
Austin, Texas, 78759, United States
Basin Orthopedic Surgical Specialists
Odessa, Texas, 79761, United States
Round Rock Orthopedics
Round Rock, Texas, 78681, United States
Unlimited Research
San Antonio, Texas, 78217, United States
Hill Country Sports Medicine
San Marcos, Texas, 78666, United States
Naval Medical Center - Portsmouth
Portsmouth, Virginia, 23708, United States
Madigan Army Medical Center
Tacoma, Washington, 98431, United States
Lifemark Health Research Group
Calgary, Alberta, T2G 5B6, Canada
Rouge Valley Health Systems
Ajax, Ontario, L1S 2J5, Canada
Fowler Kennedy Sport Medicine Clinic
London, Ontario, N6A 3K7, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Scott Houston
Omeros Corporation
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 26, 2005
First Posted
September 27, 2005
Study Start
June 1, 2005
Primary Completion
September 1, 2010
Study Completion
March 1, 2011
Last Updated
October 12, 2012
Record last verified: 2012-10